摘要
目的分析唑来膦酸联合TP方案化疗治疗晚期非小细胞肺癌(NSCLC)骨转移的效果及不良反应。方法收集本院接受治疗的晚期NSCLC骨转移患者78例,采用随机数表法分为TP化疗组和联合治疗组,各39例。TP化疗组患者接受单纯TP方案化疗,联合治疗组患者接受唑来膦酸联合TP方案化疗。对比两组患者的近期疗效、血清骨转换生化标志物含量、治疗期间不良反应发生。结果治疗3个月后,联合治疗组患者的总有效率显著高于TP化疗组(P<0.05);联合治疗组患者血清骨转换生化标志物骨碱性磷酸酶(BLAP)、Ⅰ型前胶原N-端前肽(PⅠNP)、Ⅰ型胶原羧基端肽β特殊序列(β-CTX)、β-胶原特殊序列(β-crosslaps)含量显著低于TP化疗组(P<0.05);两组患者皮疹、头痛发热、肌肉关节痛等不良反应发生率比较,差异无统计学意义(P>0.05)。结论晚期NSCLC骨转移患者接受唑来膦酸联合TP方案化疗,可有效提高近期疗效,且不增加不良反应,具有高效安全的临床应用价值。
Objective To study the efficacy and adverse reactions of zoledronic acid combined with TP chemotherapy in the treatment of advanced NSCLC bone metastasis.Methods 78 cases of advanced NSCLC bone metastasis patients in our hospital were chosen as research subject,all patients were divided into TP group and combined group each with 39 cases.Patients in the TP group were treated with TP chemotherapy only,and those in combined group were treated with zoledronic acid combined with TP chemotherapy,both lasted 3 cycles.The short-term efficacy,biochemical markers of serum bone turnover,and the incidence of adverse reactions during treatment were compared between two groups.Results Three months after treatment,total effective rate in combined group was higher than that in TP group(P<0.05);serum contents of bone metabolism index such as BLAP,PINP,β-CTX,P-crosslaps in combined group were lower than those in TP group(P<0.05);there was no statistical difference between two groups in incidence of adverse reactions such as fever,headache,muscle and joint pain(P>0.05).Conclusion Zoledronic acid combined with TP chemotherapy in patients with advanced NSCLC bone metastasis can effectively improve the short-term efficacy and will not increase the adverse reactions.It has high efficiency and safety in clinical application.
作者
赵军
刘水中
王正志
张双立
孟庆刚
ZHAO Jun;LIU Shuizhong;WANG Zhengzhi;WANG Zhengzhi;MENG Qinggang(Department of Orthopedics,Harbin First Hospital,Harbin,Heilongjiang,150010,China;Department of Ophthalmology,the First Hospital of Qiqihar,Qiqihar,Heilongjiang,161006,China;3Department of Neurosurgery,the First Hospital of Qiqihar,Qiqihar,Heilongjiang,161005,China;Harbin Medical University,Harbin,Heilongjiang,150081,China)
出处
《肿瘤药学》
CAS
2018年第3期374-377,共4页
Anti-Tumor Pharmacy
基金
黑龙江省卫生计生委科研课题(HY20130974)
作者简介
赵军,男,博士,研究方向:骨转移瘤临床研究,E-mail:limudian@163.com。;通讯作者:孟庆刚,男,博士,研究方向:骨肿瘤的基础和临床研究,E-mail:99632372@qq.com。
